GLP-1 Exit Plan
What Happens When Weight Loss Drugs Stop
Almost everything written about GLP-1 drugs is about what happens when you take them. What I want to talk about is what happens when you stop.
In 2021, a trial called STEP 1 put semaglutide on the map. Nearly 2,000 adults. Sixty-eight weeks. An average loss of just under 15 percent. But researchers kept tracking some of them after the shots stopped.
John Wilding and colleagues tracked 327 people for a year after treatment ended, 228 of them on semaglutide.
Picture one of them. She starts at 230 pounds, the group average. On the drug she loses about 40 pounds. A year after her last shot, she put 27 pounds back on. She's down 13 from where she started. Her blood pressure, blood sugar and cholesterol had improved on the drug. Most of that drifted back too.
The pattern holds across the research. In January 2026, Sam West and a team at Oxford reviewed 37 studies and 9,341 people, covering every kind of weight-loss drug. Average regain came to about 0.9 pounds a month, and for newer drugs like semaglutide and tirzepatide the estimate was closer to 1.8. Their modeling projected average weight back at the starting line in roughly 18 months.
That's weight gain about four times faster than the rate they estimated for people who lost weight and stopped under traditional diet and exercise programs.
This is NOT a willpower problem.
When you lose a lot of weight, your body fights to get it back. Hunger gets louder. Fullness gets quieter. Your metabolism runs cooler than your smaller body should need. GLP-1 drugs quiet the hunger side of that. Take the drug away and the quiet goes with it.
People losing weight on a drug don't have to consciously practice changing how they eat, so when it stops they may not have built the habits that keep it off.
That's not a reason to feel bad. It's a reason to plan.
The best clue about what helps comes out of Copenhagen. In a trial called S-LiTE, researchers led by Julie Lundgren put everyone through an eight-week low-calorie diet, then split them four ways for a year.
A. One group had supervised exercise.
B. The second group took Liraglutide, an older daily GLP-1 drug.
C. The third group did both, they had supervised exercise and took Liraglutide.
D. The final group got a placebo shot and no exercise.
The group that took Liraglutide AND exercised did best that year. The interesting part came later. Simon Birk Kjær Jensen's team brought everyone back a year after all treatment ended. During that year there was no contact. No coaching, no check-ins.
The people who had exercised and taken the drug were seven times more likely than the placebo group to still be holding a 10 percent weight loss. They were four times more likely than the drug-only group. Exercise alone beat placebo too. Over that year, the drug-only group put back about 13 pounds more than the exercise-only group.
A year after everything stopped, the two exercise groups were still reporting around 240 and 225 minutes of moderate to hard activity a week. The drug-only group reported 30 minutes. The placebo group reported 150.
This is important. People assigned the drug without exercise were moving less than the placebo group, and both had gone through the same starting diet.
The medication lends you a smaller body. Exercise can build the habits that help you keep it.
A word on muscle. A quarter to 40 percent of what people lose on these drugs is lean mass. That sounds alarming, but lean mass isn't just muscle. It also includes water and organ tissue. Some real muscle does go, especially when the loss is fast and training and protein are thin.
If you're trying to keep it off, here are three things worth trying.
1. Lift weights two or three times a week, starting while you're still on the drug, not after.
2. Eat protein on purpose. For many adults losing weight, around 1.5 grams per pound of body weight a day is a useful range. At higher weights that needs adjusting, so ask a professional.
3. Build toward about 250 minutes of activity a week. That's where the S-LiTE exercise groups landed, and it matches longstanding guidelines for keeping weight off.
If getting off it is the plan, the training has to start long before the last dose. The medication is a loan, the fitness is yours to keep.
Reference Links:
Weight regain and cardiometabolic effects after withdrawal of semaglutide: The STEP 1 trial extension
John P. H. Wilding D.M, Rachel L. Batterham MBBS, Melanie Davies M.D, Luc F. Van Gaal M.D, Kristian Kandler M.D, Katerina Konakli PhD, Ildiko Lingvay M.D, Barbara M. McGowan M.D, Tugce Kalayci Oral MD, Julio Rosenstock M.D, Thomas A. Wadden Ph.D, Sean Wharton M.D, Koutaro Yokote M.D, Robert F. Kushner M.D, STEP 1 Study Group
Diabetes, Obesity and Metabolism - A Journal of Pharmacology and Therapeutics, Published 19 April 2022
Click Here for the Study: https://doi.org/10.1111/dom.14725
Once-Weekly Semaglutide in Adults with Overweight or Obesity
John P.H. Wilding, D.M., Rachel L. Batterham, M.B., B.S., Ph.D., Salvatore Calanna, Ph.D., Melanie Davies, M.D., Luc F. Van Gaal, M.D., Ph.D., Ildiko Lingvay, M.D., M.P.H., M.S.C.S., Barbara M. McGowan, M.D., Ph.D.
The New England Journal of Medicine, Published February 10, 2021
Click Here for the Study: https://www.nejm.org/doi/full/10.1056/NEJMoa2032183
Weight regain after cessation of medication for weight management: systematic review and meta-analysis
Sam West, Jadine Scragg, Paul Aveyard, Jason L Oke, Lia Willis, Stella J P Haffner, Heather Knight, Danni Wang, Sarah Morrow, Laura Heath, Susan A Jebb, Dimitrios A Koutoukidis
the BMJ, Published 07 January 2026
Click Here for the Study: https://doi.org/10.1136/bmj-2025-085304
Healthy Weight Loss Maintenance with Exercise, Liraglutide, or Both Combined
Julie R. Lundgren, M.D., Ph.D., Charlotte Janus, Ph.D., Simon B.K. Jensen, M.Sc., Christian R. Juhl, M.D., Lisa M. Olsen, M.Sc., Rasmus M. Christensen, B.Sc.Med., Maria S. Svane, M.D., Ph.D., Thomas Bandholm, Ph.D., Kirstine N. Bojsen-Møller, M.D., Ph.D., Martin B. Blond, M.D., Ph.D., Jens-Erik B. Jensen, M.D., Ph.D., Bente M. Stallknecht, M.D., D.M.Sc., Jens J. Holst, M.D., D.M.Sc., Sten Madsbad, M.D., D.M.Sc., and Signe S. Torekov, Ph.D.
The New England Journal of Medicine, Published May 5, 2021
Click Here for the Study: https://www.nejm.org/doi/full/10.1056/NEJMoa2028198
Healthy weight loss maintenance with exercise, GLP-1 receptor agonist, or both combined followed by one year without treatment: a post-treatment analysis of a randomised placebo-controlled trial
Simon Birk Kjær Jensena ∙ Martin Bæk Blondb ∙ Rasmus Michael Sandsdala ∙ Lisa Møller Olsena ∙ Christian Rimer Juhla ∙ Julie Rehné Lundgrena ∙ Charlotte Janusa ∙ Bente Merete Stallknechta ∙ Jens Juul Holsta,c ∙ Sten Madsbadd ∙ Signe Sørensen Torekov
eClinicalMedicine - Part of THE LANCET Discovery Science, Published Volume 69102475 March 2024
Click Here for the Study: https://www.thelancet.com/journals/eclinm/article/PIIS2589-5370(24)00054-3/fulltext
Body composition changes during weight reduction with tirzepatide in the SURMOUNT-1 study of adults with obesity or overweight
Michelle Look MD, Julia P. Dunn MD, Robert F. Kushner MD, Dachuang Cao PhD, Charles Harris MD, Theresa Hunter Gibble PhD, Adam Stefanski MD, Ryan Griffin Pharm. D.
Diabetes, Obesity and Metabolism - A Journal of Pharmacology and Therapeutics, Published 25 February 2025
Click Here for the Study: https://doi.org/10.1111/dom.16275
Call for a FREE Consultation (305) 296-3434
CAUTION: Check with your doctor before
beginning any diet or exercise program.
8/13/2026
